Early Onset Cancer Research Program
We place a high value on research. The Early Onset Cancer Program partners with teams around Yale Cancer Center, Yale School of Medicine, and Yale School of Public Health to discover new insight into early onset cancers and to learn more about the needs of our patients and families.
On this page
Research at Yale
Cancer studies use large data sets to discover new drugs to treat cancer, new therapies to make symptoms less severe, or lifestyle changes to reduce the chances of getting cancer. It may also address big-picture questions like why cancer is more common in certain populations, like younger adults, or how doctors can make existing tools more effective. These discoveries can help people with cancer and their caregivers live fuller lives.
When a scientist makes a medical discovery in the laboratory (called bench research), it also needs to be tested on people outside the lab setting. These tests are known as clinical trials. Through these trials, researchers can learn if the treatment or tool is safe, learn about potential side effects, and discover how effective it is for the patients who volunteer to try it.
Research is a complex process where teams of professionals from many fields join together with one goal. The Early Onset Cancer Program also has an intentional focus on increasing diversity among participants in research and clinical trials. We are working to expand access to these studies for all adults under 50.
Our Team's Research
Learn more about our team’s active studies below:
More Research & Clinical Trials
Research
Many other experts at Yale Cancer Center are also working to learn more about early onset cancers. You can learn more about their studies below.
Clinical Trials
If you or a loved one has cancer, consider discussing clinical trials with your primary cancer care team. For people who do not have success with conventional therapies, drug treatments being tested in clinical trials can offer hope.
Trials
- Brain and Nervous System, PediatricsA Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant GliomasPrincipal Investigator: Asher Marks